-
公开(公告)号:US20210009571A1
公开(公告)日:2021-01-14
申请号:US16955926
申请日:2018-12-19
Applicant: H. Lundbeck A/S
Inventor: Jan Kehler , Lars Kyhn Rasmussen , Morten Langgârd , Mikkel Jessing , Paulo Jorge Vieira Vital , Karsten Juhl , Mauro Marigo
IPC: C07D405/14 , C07D401/14
Abstract: The present invention provides compounds of formula (I) that are PDE1 enzyme inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating disorders using the compounds of the invention.
-
公开(公告)号:US20140357639A1
公开(公告)日:2014-12-04
申请号:US14309423
申请日:2014-06-19
Applicant: H. Lundbeck A/S
Inventor: Jan Kehler , Jacob Nielsen , Mauro Marigo , John Paul Kilburn , Morten Langgârd
IPC: C07D487/04 , A61K31/437 , C07D471/04 , A61K45/06 , A61K31/4985
CPC classification number: C07D487/04 , A61K31/437 , A61K31/4985 , A61K45/06 , C07D471/04 , C07D519/00
Abstract: This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a method of treating a subject suffering from a drug addiction comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I.
Abstract translation: 本发明涉及PDE10A酶抑制剂的化合物。 本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。 本发明还提供了制备式I化合物的方法。本发明还提供了治疗患有神经变性疾病的受试者的方法,其包括向受试者施用治疗有效量的式I化合物。本发明 本发明还提供了治疗患有药物成瘾症的受试者的方法,其包括向受试者施用治疗有效量的式I化合物。本发明还提供了治疗患有精神病障碍患者的方法,包括给予 治疗有效量的式I化合物。
-